Correspondence | Published:

Bovine TB: stopping disease control would block all live exports

Nature volume 456, page 700 (11 December 2008) | Download Citation

Subjects

Sir

In their Correspondence, Paul Torgerson and David Torgerson question the importance of controlling bovine tuberculosis (TB) in the United Kingdom ('Does risk to humans justify high cost of fighting bovine TB?' Nature 455, 1029; 2008). However, they disregard the crucial role of disease control in protecting international trade — a key reason why the UK government is trying to eradicate bovine TB.

To be exported from the United Kingdom, cattle aged 42 days or older must have tested negative for bovine TB within the previous 30 days. In 1995, the value of live cattle exports was £77.6 million (US$115 million); after the imposition of the ban on exports because of BSE (bovine spongiform encephalopathy), this fell to zero (see http://tinyurl.com/6j8o2w). Although the ban on exports from the United Kingdom was lifted in 2006, live cattle exports are only just now starting to recover.

To stop control of bovine TB would once again block all live exports. UK government expenditure on the foot-and-mouth disease outbreak in 2001 was £2.79 billion, and the protection of international trade was a key driver of the control measures used at that time (see http://tinyurl.com/67p9g5).

The protection of trade status is one aspect of an integrated policy for controlling bovine TB that safeguards public health and the agricultural economy as well as animal health and welfare. Indeed, as we face an increasing problem with bovine TB in the United Kingdom, the success of this control strategy in protecting public health is evidenced by the sporadic nature of Mycobacterium bovis infections in the human population (see A. L. Gibson et al. J. Clin Microbiol. 42, 431–434; 2004; J. T. Evans et al. Lancet 369, 1270–1276; 2007). Now is not the time to dismantle controls for bovine TB.

Author information

Affiliations

  1. UCD College of Life Sciences and UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland  stephen.gordon@ucd.ie

    • Stephen V. Gordon

Authors

  1. Search for Stephen V. Gordon in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/456700b

Contributions may be submitted to correspondence@nature.com. Correspondence should be signed by no more than three authors; preferably by one. Published contributions are edited. Science publishing issues are regularly featured at Nautilus (http://blogs.nature.com/nautilus), where we welcome comments and debate.

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing